1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Finland Pharmaceuticals and Healthcare Report Q4 2016

Finland Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 69 pages

Includes 3 FREE quarterly updates

BMI View:

Finland will remain amongst the wealthiest countries in the world in real GDP per capita terms, which together with an aging population and a preference for patented medicines, will keep pharmaceutical spending high. However, long-term economic stagnation lies ahead which may push the government to continue to implement additional cost containment measures, therefore creating further revenue earning challenges for drugmakers.

Headline Expenditure Projections


- Pharmaceuticals: EUR2.98bn (USD3.30bn) in 2015 to EUR3.09bn (USD3.31bn) in 2016;+3.8% in local currency terms and +0.1% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: EUR19.50bn (USD21.63bn) in 2015 to EUR20.12bn (USD21.53bn) in 2016; +3.2% in local currency terms and -0.5% in US dollar terms. Forecast revised upwards slightly from last quarter.

Table Of Contents

Finland Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Finland 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Finland 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Finland 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Finland 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Finland 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Finland 2012-2020) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Finland 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Finland 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Finland 2014-2020) 27
Industry Risk/Reward Index 28
Western Europe Risk/Reward Index 28
Finland Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 36
Intellectual Property Issues 37
Pricing Regime 37
Reimbursement Regime 40
Market Overview 42
Healthcare Sector 43
Table: Healthcare Resources (Finland 2010-2015) 46
Table: Healthcare Personnel (Finland 2010-2015) 47
Table: Healthcare Activity (Finland 2010-2015) 47
Research And Development 47
Clinical Trials 48
Epidemiology 49
Competitive Landscape 53
Research-Based Industry 53
Table: Multinational Market Activity 54
Table: PIF Members 55
Generic Drugmakers 57
Pharmaceutical Distribution and Retail Sector 57
Demographic Forecast 58
Table: Population Headline Indicators (Finland 1990-2025) 59
Table: Key Population Ratios (Finland 1990-2025) 59
Table: Urban/Rural Population and Life Expectancy (Finland 1990-2025) 60
Table: Population By Age Group (Finland 1990-2025) 60
Table: Population By Age Group % (Finland 1990-2025) 61
Glossary 63
Methodology 65
Pharmaceutical Expenditure Forecast Model 65
Healthcare Expenditure Forecast Model 65
Notes On Methodology 66
Risk/Reward Index Methodology 67
Index Overview 68
Table: Pharmaceutical Risk/Reward Index Indicators 68
Indicator Weightings 69

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.